Aurora Cannabis Acquires Safari Flower Co. for $26.5M, Boosting EU GMP Capacity for Global Medical Markets

summarizeSummary

Aurora Cannabis Inc. announced the acquisition of Safari Flower Company for $26.5 million, significantly expanding its EU GMP certified cultivation capacity to serve growing high-margin international medical cannabis markets.

check_boxKey Events

• Strategic Acquisition Announced

  Aurora Cannabis acquired Safari Flower Company, an established EU GMP certified cannabis cultivator and manufacturer.

• Significant Consideration

  The aggregate consideration for the acquisition is valued at $26.5 million, including a $2 million contingent cash payment.

• Expanded EU GMP Capacity

  The acquisition provides a 59,000 sq ft EU GMP certified facility, increasing capacity for high-margin international medical cannabis markets.

• Expected Financial Accretion

  The transaction is anticipated to deliver positive Adjusted EBITDA contributions starting in fiscal year 2027.

auto_awesomeAnalysis

This acquisition is a substantial strategic move for Aurora Cannabis, representing a significant portion of its current market capitalization. By acquiring Safari Flower Company, Aurora gains critical EU GMP certified capacity, which is essential for expanding its presence in lucrative international medical cannabis markets like Germany, Australia, Poland, and the UK. The company expects the transaction to be accretive to Adjusted EBITDA by fiscal year 2027, indicating a positive financial impact. The deal structure, involving both cash and stock, suggests a balanced approach to financing this growth initiative. Investors should view this as a clear signal of Aurora's commitment to its medical-first, high-margin international strategy.